Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates.

Literature DB >> 22214778

In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates.

Premavathy Levasseur¹, Anne-Marie Girard, Monique Claudon, Herman Goossens, Michael T Black, Kenneth Coleman, Christine Miossec.

Abstract

The β-lactamase inhibitor avibactam (NXL104) displays potent inhibition of both class A and C enzymes. The in vitro antibacterial activity of the combination ceftazidime-avibactam was evaluated against a clinical panel of Pseudomonas aeruginosa isolates. Avibactam offered efficient protection from hydrolysis since 94% of isolates were susceptible to ceftazidime when combined with 4 μg/ml avibactam, compared with 65% susceptible to ceftazidime alone. Ceftazidime-avibactam also demonstrated better antipseudomonal activity than imipenem (82% susceptibility), a common reference treatment.

Entities: Chemical Species

Mesh：

Substances：

Year: 2012 PMID： 22214778 PMCID： PMC3294935 DOI： 10.1128/AAC.06064-11

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

9 in total

1. In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor.

Authors: Alain Bonnefoy; Claudine Dupuis-Hamelin; Valérie Steier; Carole Delachaume; Catherine Seys; Thérèse Stachyra; Monique Fairley; Michèle Guitton; Maxime Lampilas
Journal: J Antimicrob Chemother Date: 2004-07-14 Impact factor: 5.790

2. In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study).

Authors: A Walkty; M DeCorby; P R S Lagacé-Wiens; J A Karlowsky; D J Hoban; G G Zhanel
Journal: Antimicrob Agents Chemother Date: 2011-03-21 Impact factor: 5.191

3. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates.

Authors: John Quale; Simona Bratu; Jyoti Gupta; David Landman
Journal: Antimicrob Agents Chemother Date: 2006-05 Impact factor: 5.191

Review 4. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors: F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal: J Clin Microbiol Date: 1995-09 Impact factor: 5.948

5. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes.

Authors: Vincent H Tam; Cary A Rogers; Kai-Tai Chang; Jaye S Weston; Juan-Pablo Caeiro; Kevin W Garey
Journal: Antimicrob Agents Chemother Date: 2010-06-28 Impact factor: 5.191

6. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters.

Authors: Shazad Mushtaq; Marina Warner; David M Livermore
Journal: J Antimicrob Chemother Date: 2010-08-26 Impact factor: 5.790

Review 7. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Authors: Philip D Lister; Daniel J Wolter; Nancy D Hanson
Journal: Clin Microbiol Rev Date: 2009-10 Impact factor: 26.132

Review 8. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe.

Authors: M Souli; I Galani; H Giamarellou
Journal: Euro Surveill Date: 2008-11-20

9. In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases.

Authors: Thérèse Stachyra; Premavathy Levasseur; Marie-Claude Péchereau; Anne-Marie Girard; Monique Claudon; Christine Miossec; Michael T Black
Journal: J Antimicrob Chemother Date: 2009-06-02 Impact factor: 5.790

9 in total

49 in total

1. A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing.

Authors: Patricia A Bradford; Michael D Huband; Gregory G Stone
Journal: Antimicrob Agents Chemother Date: 2018-06-26 Impact factor: 5.191

2. Kinetics of avibactam inhibition against Class A, C, and D β-lactamases.

Authors: David E Ehmann; Haris Jahic; Philip L Ross; Rong-Fang Gu; Jun Hu; Thomas F Durand-Réville; Sushmita Lahiri; Jason Thresher; Stephania Livchak; Ning Gao; Tiffany Palmer; Grant K Walkup; Stewart L Fisher
Journal: J Biol Chem Date: 2013-08-02 Impact factor: 5.157

Review 3. Investigational antimicrobial agents of 2013.

Authors: Michael J Pucci; Karen Bush
Journal: Clin Microbiol Rev Date: 2013-10 Impact factor: 26.132

4. Multidrug-resistant bacteria in organ transplantation: an emerging threat with limited therapeutic options.

Authors: Gopi Patel; Meenakshi M Rana; Shirish Huprikar
Journal: Curr Infect Dis Rep Date: 2013-12 Impact factor: 3.725

5. Pharmacokinetics and penetration of ceftazidime and avibactam into epithelial lining fluid in thigh- and lung-infected mice.

Authors: Johanna Berkhout; Maria J Melchers; Anita C van Mil; Seyedmojtaba Seyedmousavi; Claudia M Lagarde; Wright W Nichols; Johan W Mouton
Journal: Antimicrob Agents Chemother Date: 2015-02-02 Impact factor: 5.191

6. Avibactam and class C β-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance.

Authors: S D Lahiri; M R Johnstone; P L Ross; R E McLaughlin; N B Olivier; R A Alm
Journal: Antimicrob Agents Chemother Date: 2014-07-14 Impact factor: 5.191